Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL15671145 | 0.85 | ABL1 (0.45) | TDP1CISD1ALDH1A1STSMAPT | |
| SCHEMBL375417 | 0.83 | ALDH1A1 (0.50) | TDP1ALDH1A1STSPTGS2CA2 | |
| SCHEMBL15649102 | 0.83 | CISD1 (0.65) | TDP1CISD1ALDH1A1STSGLA | |
| SCHEMBL28148408 | 0.82 | TDP1 (0.50) | TDP1CISD1ALDH1A1STSPTGS2 | |
| SCHEMBL7910581 | 0.82 | GLA (0.53) | TDP1CISD1STSGLAGAA | |
| SCHEMBL3042573 | 0.81 | STS (0.64) | CISD1ALDH1A1STSGLAGAA | |
| SCHEMBL28385519 | 0.81 | ALDH1A1 (0.48) | TDP1ALDH1A1STSPTGS2CA2 | |
| Ammonia Solution, Strong SCHEMBL2908474 | 0.79 | GLA (0.52) | TDP1CISD1STSGLAGAA | |
| SCHEMBL1005410 | 0.79 | ALDH1A1 (0.46) | TDP1ALDH1A1STSPTGS2CA2 | |
| SCHEMBL941732 | 0.79 | ALDH1A1 (0.46) | TDP1ALDH1A1STSGAACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20250262668-A1 | THREE-DIMENSIONAL PRINTING | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2025-08-21 | — | — | US | claimed |
| US-12358052-B2 | Three-dimensional printing | PERIDOT PRINT LLC (US) | 2025-07-15 | — | — | US | claimed |
| US-12337382-B2 | Three-dimensional printing | PERIDOT PRINT LLC (US) | 2025-06-24 | — | — | US | claimed |
| US-12251873-B2 | Three-dimensional printing | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2025-03-18 | — | — | US | claimed |
| US-12186805-B2 | Three-dimensional printing | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2025-01-07 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2001093911-A2 | MACROMOLECULAR DRUG COMPLEXES AND COMPOSITIONS CONTAINING THE SAME | THE BOARD OF TRUSTESS OF THE UNIVERSITY OF ILLINOIS (US) | 2001-12-13 | — | — | WO | claimed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | claimed |
| US-6281180-B1 | Automatic dishwashing compositions containing water soluble cationic or amphoteric polymers | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. | 2001-08-28 | — | — | US | claimed |
| EP-1060750-A2 | Method for treating amyloidosis | Queen's University at Kingston (CA) | 2000-12-20 | — | — | EP | claimed |
| US-6063370-A | DRUG, POLYMER COMPLEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-05-16 | — | — | US | claimed |
| WO-1997037680-A1 | MACROMOLECULAR COMPLEXES FOR DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1997-10-16 | — | — | WO | claimed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | claimed |
| US-5589324-A | INTERPENETRATING POLYMER NETWORKS | INTERNATIONAL PAPER COMPANY (US) | 1996-12-31 | — | — | US | claimed |
| EP-0691844-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-01-17 | — | — | EP | claimed |
| WO-1994022437-A2 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1994-10-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | TDP1 3493/4885CISD1 3448/4885ALDH1A1 822/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | TDP1 4164/4885CISD1 3667/4885ALDH1A1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.